Ticker Details
Cyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Inc mainly develops targeted medicines for cancer and other proliferative diseases. The company focuses in hematology and oncology-based development pipeline of novel drug candidates.
IPO Date:	April 1, 2004
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$15.16M
Activated in VL:	False

Average Daily Range
Avg Daily Range:	$0.12 | 4.33%
Avg Daily Range (30 D):	$0.16 | 2.49%
Avg Daily Range (90 D):	$0.16 | 2.49%

Institutional Daily Volume
Avg Daily Volume:	.42M
Avg Daily Volume (30 D):	M
Avg Daily Volume (90 D):	M

Trade Size
Avg Trade Size (Sh.):	312
Avg Trade Size (Sh.) (30 D):	96
Avg Trade Size (Sh.) (90 D):	96

Institutional Trades
Total Institutional Trades:	50
Avg Institutional Trade:	$1.05M
Avg Institutional Trade (30 D):	$.69M
Avg Institutional Trade (90 D):	$.69M
Avg Institutional Trade Volume:	.02M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.48M
Avg Closing Trade (30 D):	$M
Avg Closing Trade (90 D):	$M
Avg Closing Volume:	.05K

News

Aug 4, 2025 @ 10:50 PM CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DA... Source: Cyclacel Pharmaceuticals

Jul 7, 2025 @ 10:00 AM CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EX... Source: Datuk Dr. Doris Wong Sing Ee

Jul 7, 2025 @ 10:00 AM CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF... Source: Cyclacel Pharmaceuticals

May 15, 2025 @ 4:50 AM CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FIN... Source: Cyclacel Pharmaceuticals, Inc.

Feb 27, 2025 @ 6:38 PM Cyclacel Pharmaceuticals Announces Closing of a Ch... Source: N/A

Financials
	TTM	Q2 2025	Q1 2025
Basic EPS	$485.06	$-.98	$
Diluted EPS	$485.06	$-.98	$
Revenue	$.08M	$M	$M
Gross Profit
Net Income / Loss	$-5.44M	$-1.32M	$-.08M
Operating Income / Loss	$-9.17M	$-1.32M	$-5.04M
Cost of Revenue
Net Cash Flow	$M	$M	$M
PE Ratio